Market Overview:
The global alectinib drugs market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of lung cancer, rising demand for targeted therapies, and growing awareness about alectinib drugs. By type, the global alectinib drugs market is segmented into 56 capsules/bottle and 240 capsules/bottle. The 240 capsules/bottle segment is expected to grow at a higher CAGR than the 56 capsules/bottle segment during the forecast period. This can be attributed to the increasing preference for long-term treatment options among patients with lung cancer. By application, the global alectinib drugs market is divided into hospital and drug store segments.
Product Definition:
Alectinib is a drug that is used to treat certain types of cancer. It belongs to a class of drugs called tyrosine kinase inhibitors. It works by blocking the activity of proteins that help cancer cells grow and spread.
56 Capsules/Bottle:
56 capsules/bottle is a drug delivery form of Alectinib. 56-capsules/bottle is an oral solid dosage form containing the active ingredient, which is used for the treatment of cancer. It’s a patented technology by Novartis AG that enables high concentration doses to be delivered in microspheres, which are then absorbed by the body more quickly than conventional tablets or capsules.
240 Capsules/Bottle:
240 capsules/bottle is the standard dosage of Alectinib drug. It contains 4 mg of Alectinib and it’s used for treatment of advanced renal cell carcinoma (RCC). The bottle contains 120 white opaque capsules, each containing a different dose.
Application Insights:
The market is segmented by application into hospital and drugs store. The hospital segment dominated the global alectinib drugs market in 2017, owing to the high usage rate of this drug for treating cancer. Alectinib is used as an alternative therapy for patients who have progressed on other therapies or are unresponsive to other therapies. It has also been found effective against angina (chest pain) due to coronary artery disease and heart failure caused due to cardiomyopathy or arrhythmia caused due to bradyarrhythmia syndrome.
Alectinib finds use as second-line treatment after first-line chemotherapy in the treatment of non-small cell lung cancer, which has spread despite initial chemotherapy; it is also used along with cisplatin for second line therapy in small cell lung cancer that has recurred following platinum based chemotherapeutic treatments.
Regional Analysis:
North America dominated the global alectinib drugs market in 2017. This is attributed to the presence of key players, high adoption of R&D services and products, well-established healthcare infrastructure, and favorable reimbursement policies & regulatory reforms. The U.S., which accounted for more than 80% share in North America market in 2017 owing to its well-developed healthcare sector and rapid economic growth also happens to be one of the top manufacturing hubs for pharmaceuticals globally with around 40% share of total pharmaceutical production worldwide.
Asia Pacific region is expected to witness lucrative growth over the forecast period owing to increasing disposable income levels coupled with rising demand for cost-effective medicines especially among patients living with cancer & chronic diseases such as diabetes & hypertension who require long term treatment decisions along with continuous therapy over a defined period thereby driving drug sales through retail pharmacies rather than through medical stores or hospitals thus boosting regional revenue generation capacity during this time frame.
Growth Factors:
- Increasing incidence of non-small cell lung cancer (NSCLC)
- Rising demand for targeted therapies for NSCLC
- Growing number of clinical trials for alectinib drugs
- increasing healthcare expenditure by governments and private players to support the growth of the market
- Technological advancements in drug delivery systems
Scope Of The Report
Report Attributes
Report Details
Report Title
Alectinib Drugs Market Research Report
By Type
56 Capsules/Bottle, 240 Capsules/Bottle
By Application
Hospital, Drugs Store
By Companies
Roche, Roche
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
132
Number of Tables & Figures
93
Customization Available
Yes, the report can be customized as per your need.
Global Alectinib Drugs Market Report Segments:
The global Alectinib Drugs market is segmented on the basis of:
Types
56 Capsules/Bottle, 240 Capsules/Bottle
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Drugs Store
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Roche
Highlights of The Alectinib Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 56 Capsules/Bottle
- 240 Capsules/Bottle
- By Application:
- Hospital
- Drugs Store
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Alectinib Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Alectinib is a drug used to treat cancer. It works by stopping the growth of cancer cells.
Some of the key players operating in the alectinib drugs market are Roche, Roche.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Alectinib Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Alectinib Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Alectinib Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Alectinib Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Alectinib Drugs Market Size & Forecast, 2018-2028
4.5.1 Alectinib Drugs Market Size and Y-o-Y Growth
4.5.2 Alectinib Drugs Market Absolute $ Opportunity
Chapter 5 Global Alectinib Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Alectinib Drugs Market Size Forecast by Type
5.2.1 56 Capsules/Bottle
5.2.2 240 Capsules/Bottle
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Alectinib Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Alectinib Drugs Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Drugs Store
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Alectinib Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Alectinib Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Alectinib Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Alectinib Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Alectinib Drugs Market Size Forecast by Type
9.6.1 56 Capsules/Bottle
9.6.2 240 Capsules/Bottle
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Alectinib Drugs Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Drugs Store
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Alectinib Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Alectinib Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Alectinib Drugs Market Size Forecast by Type
10.6.1 56 Capsules/Bottle
10.6.2 240 Capsules/Bottle
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Alectinib Drugs Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Drugs Store
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Alectinib Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Alectinib Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Alectinib Drugs Market Size Forecast by Type
11.6.1 56 Capsules/Bottle
11.6.2 240 Capsules/Bottle
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Alectinib Drugs Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Drugs Store
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Alectinib Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Alectinib Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Alectinib Drugs Market Size Forecast by Type
12.6.1 56 Capsules/Bottle
12.6.2 240 Capsules/Bottle
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Alectinib Drugs Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Drugs Store
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Alectinib Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Alectinib Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Alectinib Drugs Market Size Forecast by Type
13.6.1 56 Capsules/Bottle
13.6.2 240 Capsules/Bottle
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Alectinib Drugs Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Drugs Store
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Alectinib Drugs Market: Competitive Dashboard
14.2 Global Alectinib Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Roche
14.3.2 Roche
